A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

Mansfield, J. C., Parkes, M., Hawthorne, A. B., Forbes, A. ORCID: https://orcid.org/0000-0001-7416-9843, Probert, C. S. J., Perowne, R. C., Cooper, A., Zeldis, J. B., Manning, D. C. and Hawkey, C. J. (2007) A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Alimentary Pharmacology and Therapeutics, 26 (3). pp. 421-430. ISSN 0269-2813

Full text not available from this repository. (Request a copy)

Abstract

Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

Item Type:	Article
Uncontrolled Keywords:	adolescent,adult,aged,crohn disease,double-blind method,female,humans,immunosuppressive agents,male,middle aged,placebos,severity of illness index,thalidomide,treatment outcome,venous thrombosis
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:50
Last Modified:	04 Mar 2024 16:54
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49680
DOI:	10.1111/j.1365-2036.2007.03385.x

Actions (login required)

View Item